Johnson & Johnson company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The company’s update to its robotic bronchoscopy platform cleared the FDA through the 510(k) pathway, adding AI-assisted planning and navigation plus upgrades aimed at improving imaging used during lung procedure guidance.
THE APEX TIMES
THE APEX TIMES
Bristol Myers Squibb and Johnson & Johnson are among the large companies drawing attention to Seaport Therapeutics after the biotech went public, following a strategy pitch built around prodrug development and board-level connections to recent neuroscience deals.
THE APEX TIMES
A new analysis of Johnson & Johnson’s (JNJ) recent trading suggests the stock has distinguished itself even as the benchmark index has moved little, with the “market’s” contribution to the stock’s overall performance appearing relatively small.
THE APEX TIMES
A dividend hike announced earlier this year adds to Johnson & Johnson’s long-running reputation for shareholder income, according to a recent Yahoo Finance analysis.
THE APEX TIMES
The healthcare giant said second-quarter sales increased 6.6% to $25.31 billion, alongside guidance that nudged its 2026 outlook higher, helping lift the stock despite a broadly selective market.
THE APEX TIMES
The medical device company received U.S. regulatory clearance for a software update to its robotic-assisted bronchoscopy platform, adding AI-powered tools aimed at supporting clinicians during lung procedures.
THE APEX TIMES
A market-focused analysis of Johnson & Johnson shares highlights a divergence between discounted cash-flow estimates and the company’s earnings-driven valuation metrics.
THE APEX TIMES
A recent Yahoo Finance check suggests Johnson & Johnson’s stock movement in the roughly month after its latest earnings report may be tied to how Wall Street’s expectations for future results are shifting.
THE APEX TIMES
A Yahoo Finance report framed Johnson & Johnson’s latest talc litigation settlement at about $5.5 billion as either a meaningful step toward resolution or a pause before additional payments, as the company navigates long-running product liability claims.
